Ping An-backed health services provider Fullerton could theoretically seek an acquisition deal or spin off its digital division.

Pfizer and Lundbeck scored exits as blood-disease therapy developer Imara raised $75.2m, floating at the foot of its range.

The genetic therapy developer, which had raised $126m in funding from investors including Eli Lilly and Access Industries, added $32.4m to the offering.

Underwriters have exercised their over-allotment option in full, increasing the University of Pennsylvania-linked genetic medicine developer’s proceeds by $32.4m.

The wages advance service has been acquired by working capital financing supplier Greensill after raising $2.5m from investors including NAB in early 2019.

Cemex Ventures has exited concrete analysis technology developer Concrete Sensors having participated in a $2.9m round less than two years ago.

Robert Bosch Venture Capital has exited Modcam after investing $600,000 in the computer vision sensor developer in 2015.

Blackstone is paying an undisclosed amount for a majority share in the health plan management software provider, which raised $34m from Medica in 2017.

The Pharmaron-backed cancer therapy developer is targeting $100m in an initial public offering preceded by $162m in funding.

Novartis and Harel are among the investors set to exit the cancer therapy developer, which also counts Bristol-Myers Squibb as a shareholder.